Mechanistic comparison of apixaban [Supplementary Concept] and razaxaban based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
2
Shared Targets
33%
Jaccard Similarity
34%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
apixaban and razaxaban share 2 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.333 means 33% of the combined target set is bound by both compounds. The IDF-weighted score of 0.336 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do apixaban and razaxaban have in common?
apixaban and razaxaban share 2 molecular targets with a Jaccard similarity of 33%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can apixaban and razaxaban be combined?
apixaban and razaxaban share 2 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: apixaban or razaxaban?
In the BiohacksAI corpus: apixaban has 997 PubMed-indexed studies, razaxaban has 0 studies.